News Sentiment

MGX sentiment intelligence

Metagenomi, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.24 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-2.4% over one week, +3.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Metagenomi Therapeutics (MGX) Edges Higher as Stock Tests Key Resistance Near $1.41 - Small Cap Breakouts

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -2.4% Price reacting lower
Trend fit Trend inactive 3.3% over four weeks
Fair value -60.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 31
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 7
Stock Titan 4
Barron's 4
simplywall.st 3
Investing.com Nigeria 2
Investing.com 2
eciks.org 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 17
Analyst action 3
Regulatory and legal 1
Capital return 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Investing.com Nigeria Direct company coverage

Chardan initiates Metagenomi stock with buy, $5 target on gene therapy potential

Chardan has initiated coverage on Metagenomi Inc (NASDAQ:MGX) with a buy rating and a $5.00 price target, citing the potential of its lead asset, MGX-001, as a one-time curative treatment for Hemophilia A. The firm believes MGX-001's proprietary gene editing approach is superior

Tone
Positive 80/100
Event
Analyst action
Published
08 Jul 2026 06:40
Source
Investing.com Nigeria
Moomoo Direct company coverage

Chardan Cuts Price Target on Metagenomi to $5 From $7, Keeps Buy Rating

Chardan has revised its price target for Metagenomi (MGX) down to $5 from $7, while maintaining a Buy rating on the stock. This adjustment comes despite the retained positive outlook from the analyst firm. Investors should note this change in valuation target.

Tone
Negative 33/100
Event
Analyst action
Published
07 Jul 2026 17:41
Source
Moomoo
GuruFocus Direct company coverage

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

Rosen Law Firm reminds investors who purchased Metagenomi, Inc. (NASDAQ: MGX) stock during its IPO between February 9-13, 2024, of the November 25, 2024, lead plaintiff deadline for a class action lawsuit. The lawsuit alleges that Metagenomi misrepresented its relationship with M

Tone
Neutral 50/100
Event
Regulatory and legal
Published
06 Jul 2026 18:40
Source
GuruFocus
TradingView Direct company coverage

MGX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Metagenomi Therapeutics, Inc. (MGX) stock, including analyst opinions, historical performance data, and key financial metrics. It highlights that analysts project a maximum price of $9.00 and a minimum of $5.00 for MGX, while

Tone
Neutral 50/100
Event
Analyst action
Published
29 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX

This article focuses on the "Price to earnings forward" metric for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). It is a financial data point presented within the context of TradingView's platform, indicating a specific financial valuation for the company.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 02:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX

The article indicates the "Price to book forward" for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). It provides basic financial information and market data for the company on TradingView. The content appears to be a stub or a section of a larger financial data page rather than a f

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX

This article provides the "Price to sales forward" metric for Metagenomi Therapeutics, Inc. (NASDAQ: MGX). The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, alongside standard disclaimers from data providers like ICE

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Metagenomi Therapeutics, Inc. Actuals & Estimates (NASDAQ:MGX)

This article provides an overview of Metagenomi Therapeutics, Inc. (NASDAQ: MGX) stock performance, analyst forecasts, and key financial data. It covers the current stock price, historical highs and lows, volatility, earnings per share, revenue, net income, and upcoming earnings

Tone
Negative 39/100
Event
Earnings
Published
26 Jun 2026 05:39
Source
TradingView
TradingKey Direct company coverage

Metagenomi Inc (MGX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a detailed overview of Metagenomi Inc (MGX) stock, focusing on its dividend and stock split history, which currently shows no data for either. It includes current stock performance metrics such as market cap and price changes. The page also features an overvi

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 11:10
Source
TradingKey
Stock Titan Direct company coverage

Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares

Metagenomi Therapeutics (MGX) director Dere Willard H was granted stock options for 21,000 shares of common stock. The options have an exercise price of $1.23 per share and will expire on June 8, 2036. These options will vest fully on the earlier of one year from the grant date o

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 18:39
Source
Stock Titan
Stock Titan Direct company coverage

Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23

Metagenomi Therapeutics (MGX) director Reid Laurence was granted 17,400 stock options with an exercise price of $1.23 per share, expiring on June 8, 2036. These options will vest on the earlier of one year from the grant date or the company’s 2027 annual stockholder meeting, cont

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 18:39
Source
Stock Titan
Stock Titan Direct company coverage

Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23

Metagenomi Therapeutics director Eric Bjerkholt was granted stock options for 21,000 shares of common stock at an exercise price of $1.23 per share. These options will vest and become exercisable on the earlier of one year from the grant date or the company's 2027 annual meeting

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 17:49
Source
Stock Titan
Stock Titan Direct company coverage

Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike

Metagenomi Therapeutics, Inc. director Juergen Eckhardt was granted 21,000 stock options with an exercise price of $1.23 per share and an expiration date of June 8, 2036. The options will vest either on the one-year anniversary of the grant date or the company's 2027 annual meeti

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 17:38
Source
Stock Titan
Investing.com Direct company coverage

Metagenomi CEO Jian Irish sells $4,854 in company stock

Metagenomi's CEO, Jian Irish, sold 3,737 shares of the company's common stock amounting to $4,854. This transaction was an automatic sale to cover tax withholding obligations related to restricted stock units rather than a discretionary trade. Following the sale, Ms. Irish direct

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 19:10
Source
Investing.com
Investing.com Direct company coverage

Metagenomi CFO Pamela Wapnick sells $3,746 of company stock

Metagenomi CFO Pamela Wapnick sold 2,884 shares of company stock worth approximately $3,746 on June 5, 2026, to satisfy tax withholding obligations related to vested restricted stock units. This was not a volitional trade, and she now directly owns 208,491 shares. The company's s

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 19:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com

Metagenomi Therapeutics, Inc. CFO Pamela Wapnick sold 2,884 shares of company stock worth approximately $3,746 due to tax withholding obligations upon the vesting of restricted stock units. This transaction was not a volitional trade. The company's stock, NASDAQ:MGX, is trading n

Tone
Negative 38/100
Event
Market update
Published
10 Jun 2026 18:11
Source
Investing.com Nigeria
Investing.com Australia Direct company coverage

Metagenomi CEO Jian Irish sells $4,854 in company stock By Investing.com

Metagenomi CEO Jian Irish sold 3,737 shares of Metagenomi Therapeutics (NASDAQ:MGX) common stock for $4,854 to cover tax withholding obligations related to restricted stock units. This was an automatic, non-discretionary transaction. Following the sale, Ms. Irish directly holds 3

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 17:30
Source
Investing.com Australia